Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the companyâs inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901. Source
No articles found.
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...
Connectyx Technologies Holdings Group, Inc. pro...
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Join the National Investor Network and get the latest information with your interests in mind.